Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Mr. Pink's Picks: selected event-driven value investments -- Ignore unavailable to you. Want to Upgrade?

To: benchpress550 who wrote (17672)	4/26/2003 11:55:36 PM
From: Ben Wa	Read Replies (2) \| Respond to of 18998

although historically, the administration of taxol has been problematic, experience over the years has greatly lessened the potential difficulties of therapy using taxol. Therefore, comparing the potential clinical advantages of a tweaked taxol such as that being developed by several firms can have significant room for variation in how the drugs are used. Essentially, the potential advantage of tweaked taxols are less than they used to be. One also wonders what happened with the Korean firm. the author of the article in street.com was unaware of that, I suppose. I mean, I thought I saw the ball under the second cup, but when the cup was lifted, the space was empty.